These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 30249700

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.
    Louie A, Grasso C, Bahniuk N, Van Scoy B, Brown DL, Kulawy R, Drusano GL.
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2646-54. PubMed ID: 20368395
    [Abstract] [Full Text] [Related]

  • 6. Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model.
    Louie A, Maynard M, Duncanson B, Nole J, Vicchiarelli M, Drusano GL.
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581114
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
    Montero MM, Domene Ochoa S, López-Causapé C, VanScoy B, Luque S, Sorlí L, Campillo N, Padilla E, Prim N, Segura C, Pomar V, Rivera A, Grau S, Ambrose PG, Oliver A, Horcajada JP.
    J Glob Antimicrob Resist; 2019 Sep; 18():37-44. PubMed ID: 31154007
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
    Rees VE, Yadav R, Rogers KE, Bulitta JB, Wirth V, Oliver A, Boyce JD, Peleg AY, Nation RL, Landersdorfer CB.
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.
    Pan AJ, Mei Q, Ye Y, Li HR, Liu B, Li JB.
    J Antibiot (Tokyo); 2017 Feb; 70(2):166-173. PubMed ID: 27756910
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J, Benavent E, Sierra Y, El Haj C, Soldevila L, Torrejón B, Rigo-Bonnin R, Tubau F, Ariza J, Murillo O.
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model.
    Montero M, VanScoy BD, López-Causapé C, Conde H, Adams J, Segura C, Zamorano L, Oliver A, Horcajada JP, Ambrose PG.
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530842
    [Abstract] [Full Text] [Related]

  • 18. Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.
    McCaughey G, Diamond P, Elborn JS, McKevitt M, Tunney MM.
    PLoS One; 2013 May; 8(7):e69763. PubMed ID: 23936095
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamic Analysis of Meropenem and Fosfomycin Combination Against Carbapenem-Resistant Acinetobacter baumannii in Patients with Normal Renal Clearance: Can It Be a Treatment Option?
    Mohd Sazlly Lim S, Heffernan AJ, Roberts JA, Sime FB.
    Microb Drug Resist; 2021 Apr; 27(4):546-552. PubMed ID: 32898467
    [Abstract] [Full Text] [Related]

  • 20. Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.
    Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Rogers KE, McGregor MJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB.
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.